Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The rationale for immunosuppressive therapy for HIV infection

The rationale for immunosuppressive therapy for HIV infection Jeffrey M. Jacobson Purpose of review Introduction This article reviews the characteristics of HIV-associated The etiologic agent for the acquired immune deficiency immune activation, describes its prognostic significance syndrome (AIDS) is the human immunodeficiency virus and highlights the lack of knowledge of the mechanism by (HIV). Treatment of this viral infection with potent which HIV-1 infection induces this phenomenon. combination antiretroviral chemotherapy results in a Recent findings dramatic reduction in AIDS-associated illness and other A recent cohort analysis found that the level of HIV-1 RNA in manifestations of the disease [1]. Over the years, anti- plasma has only minimal predictive value for the rate of retroviral therapy has become simpler, more tolerable and decline of the CD4þ T-lymphocyte count in an individual less toxic. Newer agents are continually being developed patient infected with HIV-1. This suggests that factors in to treat drug-resistant virus and reduce toxicities further. addition to viral replication must play an important role in the Still, not all of those infected have benefited fully from genesis of immune deficiency in HIV-1 infection, and has these advances. Drug resistance, adverse effects and rekindled interest in the generalized T-cell activation incomplete antiviral response occur in many. A substan- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

The rationale for immunosuppressive therapy for HIV infection

Jacobson, Jeffrey M
Current Opinion in HIV and Aids , Volume 2 (3) – May 1, 2007
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/the-rationale-for-immunosuppressive-therapy-for-hiv-infection-h144BEOldi

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e3280b01848
pmid
19372888
Publisher site
See Article on Publisher Site

Abstract

Jeffrey M. Jacobson Purpose of review Introduction This article reviews the characteristics of HIV-associated The etiologic agent for the acquired immune deficiency immune activation, describes its prognostic significance syndrome (AIDS) is the human immunodeficiency virus and highlights the lack of knowledge of the mechanism by (HIV). Treatment of this viral infection with potent which HIV-1 infection induces this phenomenon. combination antiretroviral chemotherapy results in a Recent findings dramatic reduction in AIDS-associated illness and other A recent cohort analysis found that the level of HIV-1 RNA in manifestations of the disease [1]. Over the years, anti- plasma has only minimal predictive value for the rate of retroviral therapy has become simpler, more tolerable and decline of the CD4þ T-lymphocyte count in an individual less toxic. Newer agents are continually being developed patient infected with HIV-1. This suggests that factors in to treat drug-resistant virus and reduce toxicities further. addition to viral replication must play an important role in the Still, not all of those infected have benefited fully from genesis of immune deficiency in HIV-1 infection, and has these advances. Drug resistance, adverse effects and rekindled interest in the generalized T-cell activation incomplete antiviral response occur in many. A substan-

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: May 1, 2007

There are no references for this article.